Grufity logo
Grufity logo
KPRX

KPRX - Kiora Pharmaceuticals, Inc. Stock Price, Fair Value and News

$2.65+0.19 (+7.72%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

83/100

KPRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

83/100

KPRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

KPRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KPRX Price Action

Last 7 days

-2.3%

Last 30 days

0.8%

Last 90 days

20%

Trailing 12 Months

-16.6%

KPRX RSI Chart

KPRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KPRX Valuation

Market Cap

9.8M

Price/Earnings (Trailing)

-0.89

Price/Sales (Trailing)

0.7

EV/EBITDA

0.09

Price/Free Cashflow

-0.93

KPRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

KPRX Fundamentals

KPRX Revenue

Revenue (TTM)

16.0M

KPRX Earnings

Earnings (TTM)

-11.1M

Earnings Growth (Yr)

-10.26%

Earnings Growth (Qtr)

62.89%

KPRX Profitability

EBT Margin

-77.81%

Return on Equity

-79.37%

Return on Assets

-52.1%

Free Cashflow Yield

-107.23%

KPRX Investor Care

Shares Dilution (1Y)

33.08%

Diluted EPS (TTM)

-2.7

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202416.0M16.0M16.0M16.0M
20193.2M3.0M2.7M2.7M
20181.3M1.4M1.7M1.7M
2017603.8K538.4K473.0K407.5K
2016---669.3K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Kiora Pharmaceuticals, Inc.

KPRX
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
 CEO
 WEBSITEkiorapharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES12

Kiora Pharmaceuticals, Inc. Frequently Asked Questions

KPRX is the stock ticker symbol of Kiora Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Kiora Pharmaceuticals, Inc. is 9.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, KPRX's PE ratio (Price to Earnings) is -0.89 and Price to Sales (PS) ratio is 0.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KPRX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Kiora Pharmaceuticals, Inc. has provided -0.485 (multiply by 100 for percentage) rate of return.